scholarly journals Xuesaitong Capsule For Patients After Percutaneous Coronary Intervention For Unstable Angina: Study Protocol For a Randomized Controlled Trial

2021 ◽  
Author(s):  
Yanqiao Yu ◽  
Shengyao Li ◽  
Wenhui Duan ◽  
Jinwen Luo ◽  
Yihan Zhao ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Percutaneous Coronary Intervention ◽  
Unstable Angina ◽  
Conventional Treatment ◽  
Controlled Trial ◽  
Blood Lipid ◽  
Coronary Intervention ◽  
Controlled Clinical Trial ◽  
Clinical Trial Registry ◽  
Percutaneous Coronary

Abstract • Background: This study was designed to investigate the effect of Xuesaitong (XST) capsule added to conventional treatment in patients after percutaneous coronary intervention (PCI) for unstable angina (UA).• Methods: This is a 12-week, randomized, multi-center, double-blinded, placebo-controlled clinical trial. A total of 120 patients with UA will be recruited and randomly allocated in a 1:1 ratio to receive XST or placebo (2 capsules twice per day) on the background of conventional treatment. The changed level of high-sensitivity C-reactive protein from baseline to week 12 is the primary outcome. Secondary outcomes include tumor necrosis factor-α, interleukin-6, platelet aggregation, blood lipid, angina symptoms and ST segment deviation in electrocardiogram. The safety of XST will be monitored during the trial.• Discussion: This study will provide an evidence regarding the efficacy and safety of XST on the background of conventional medical treatment in patients after PCI for UA.• Trial registration: Chinese Clinical Trial Registry, ChiCTR2000032152. Registered on 14 January 2020.

scholarly journals The Effects of Xuefu Zhuyu and Shengmai on the Evolution of Syndromes and Inflammatory Markers in Patients with Unstable Angina Pectoris after Percutaneous Coronary Intervention: A Randomised Controlled Clinical Trial

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Jie Wang ◽  
Xiaochen Yang ◽  
Fuyong Chu ◽  
Jianxin Chen ◽  
Qingyong He ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Angina Pectoris ◽  
Unstable Angina ◽  
Inflammatory Markers ◽  
Blood Stasis ◽  
High Sensitivity ◽  
Coronary Intervention ◽  
Unstable Angina Pectoris ◽  
Controlled Clinical Trial ◽  
Percutaneous Coronary

We evaluated the effects of the Xuefu Zhuyu capsule (XFZY) and the Shengmai capsule (SM) on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris (UAP) after percutaneous coronary intervention (PCI). Ninety patients with UAP after PCI were randomly and equally assigned to three groups: the XFZY group, the SM group, and the placebo group, with 30 patients in each group. Six syndrome factors (including Qi deficiency, yin deficiency, yang deficiency, blood stasis, phlegm, and Qi stagnation) and 4 inflammatory markers (high-sensitivity C-reactive protein (Hs-CRP), endothelins-1 (ET-1), matrix metalloproteinases-9 (MMP-9), and homocysteine (Hcy)) were observed at week 0 and at the 1st, 4th and 12th weeks. In conclusion, the evolution of syndromes present in patients with UAP after PCI followed these trends (1) The deficiency syndromes gradually increased during a 12-week period, but the excess syndromes first gradually decreased and then mildly increased after PCI. (2) XFZY and SM can prevent excess syndromes from increasing in the later stages and prevent deficiency syndromes from increasing in all stages. (3) XFZY and SMcan reduce the levels of the inflammatory markers, especially in the later stages after PCI.

Sign in / Sign up

Export Citation Format

Share Document